211 related articles for article (PubMed ID: 36430448)
1. MUC1 Tissue Expression and Its Soluble Form CA15-3 Identify a Clear Cell Renal Cell Carcinoma with Distinct Metabolic Profile and Poor Clinical Outcome.
Lucarelli G; Rutigliano M; Loizzo D; di Meo NA; Lasorsa F; Mastropasqua M; Maiorano E; Bizzoca C; Vincenti L; Battaglia M; Ditonno P
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430448
[TBL] [Abstract][Full Text] [Related]
2. The Role of MUC1 in Renal Cell Carcinoma.
Milella M; Rutigliano M; Lasorsa F; Ferro M; Bianchi R; Fallara G; Crocetto F; Pandolfo SD; Barone B; d'Amati A; Spilotros M; Battaglia M; Ditonno P; Lucarelli G
Biomolecules; 2024 Mar; 14(3):. PubMed ID: 38540735
[TBL] [Abstract][Full Text] [Related]
3. MUC1 Expression Affects the Immunoflogosis in Renal Cell Carcinoma Microenvironment through Complement System Activation and Immune Infiltrate Modulation.
Lucarelli G; Netti GS; Rutigliano M; Lasorsa F; Loizzo D; Milella M; Schirinzi A; Fontana A; Di Serio F; Tamma R; Ribatti D; Battaglia M; Ranieri E; Ditonno P
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902242
[TBL] [Abstract][Full Text] [Related]
4. Increased Expression of the Autocrine Motility Factor is Associated With Poor Prognosis in Patients With Clear Cell-Renal Cell Carcinoma.
Lucarelli G; Rutigliano M; Sanguedolce F; Galleggiante V; Giglio A; Cagiano S; Bufo P; Maiorano E; Ribatti D; Ranieri E; Gigante M; Gesualdo L; Ferro M; de Cobelli O; Buonerba C; Di Lorenzo G; De Placido S; Palazzo S; Bettocchi C; Ditonno P; Battaglia M
Medicine (Baltimore); 2015 Nov; 94(46):e2117. PubMed ID: 26579829
[TBL] [Abstract][Full Text] [Related]
5. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
[TBL] [Abstract][Full Text] [Related]
6. MUC1, a new hypoxia inducible factor target gene, is an actor in clear renal cell carcinoma tumor progression.
Aubert S; Fauquette V; Hémon B; Lepoivre R; Briez N; Bernard D; Van Seuningen I; Leroy X; Perrais M
Cancer Res; 2009 Jul; 69(14):5707-15. PubMed ID: 19549898
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of placenta specific 8 is associated with malignant progression and poor prognosis of clear cell renal cell carcinoma.
Shi L; Xiao L; Heng B; Mo S; Chen W; Su Z
Int Urol Nephrol; 2017 Jul; 49(7):1165-1176. PubMed ID: 28349447
[TBL] [Abstract][Full Text] [Related]
8. Activation of the kynurenine pathway predicts poor outcome in patients with clear cell renal cell carcinoma.
Lucarelli G; Rutigliano M; Ferro M; Giglio A; Intini A; Triggiano F; Palazzo S; Gigante M; Castellano G; Ranieri E; Buonerba C; Terracciano D; Sanguedolce F; Napoli A; Maiorano E; Morelli F; Ditonno P; Battaglia M
Urol Oncol; 2017 Jul; 35(7):461.e15-461.e27. PubMed ID: 28359744
[TBL] [Abstract][Full Text] [Related]
9. Multi-omic profiling of clear cell renal cell carcinoma identifies metabolic reprogramming associated with disease progression.
Hu J; Wang SG; Hou Y; Chen Z; Liu L; Li R; Li N; Zhou L; Yang Y; Wang L; Wang L; Yang X; Lei Y; Deng C; Li Y; Deng Z; Ding Y; Kuang Y; Yao Z; Xun Y; Li F; Li H; Hu J; Liu Z; Wang T; Hao Y; Jiao X; Guan W; Tao Z; Ren S; Chen K
Nat Genet; 2024 Mar; 56(3):442-457. PubMed ID: 38361033
[TBL] [Abstract][Full Text] [Related]
10. ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma.
Brooks SA; Brannon AR; Parker JS; Fisher JC; Sen O; Kattan MW; Hakimi AA; Hsieh JJ; Choueiri TK; Tamboli P; Maranchie JK; Hinds P; Miller CR; Nielsen ME; Rathmell WK
Eur Urol; 2014 Jul; 66(1):77-84. PubMed ID: 24613583
[TBL] [Abstract][Full Text] [Related]
11. Integration of Lipidomics and Transcriptomics Reveals Reprogramming of the Lipid Metabolism and Composition in Clear Cell Renal Cell Carcinoma.
Lucarelli G; Ferro M; Loizzo D; Bianchi C; Terracciano D; Cantiello F; Bell LN; Battaglia S; Porta C; Gernone A; Perego RA; Maiorano E; Cobelli O; Castellano G; Vincenti L; Ditonno P; Battaglia M
Metabolites; 2020 Dec; 10(12):. PubMed ID: 33322148
[TBL] [Abstract][Full Text] [Related]
12. Prognostic implications of Aquaporin 9 expression in clear cell renal cell carcinoma.
Xu WH; Shi SN; Xu Y; Wang J; Wang HK; Cao DL; Shi GH; Qu YY; Zhang HL; Ye DW
J Transl Med; 2019 Nov; 17(1):363. PubMed ID: 31703694
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of long non-coding RNA ENSG00000241684 is associated with poor prognosis in advanced clear cell renal cell carcinoma.
Su H; Wang H; Shi G; Zhang H; Sun F; Ye D
Eur J Surg Oncol; 2018 Jun; 44(6):840-846. PubMed ID: 29433989
[TBL] [Abstract][Full Text] [Related]
14. MCT1 expression is independently related to shorter cancer-specific survival in clear cell renal cell carcinoma.
de Carvalho PA; Bonatelli M; Cordeiro MD; Coelho RF; Reis S; Srougi M; Nahas WC; Pinheiro C; Leite KRM
Carcinogenesis; 2021 Dec; 42(12):1420-1427. PubMed ID: 34668521
[TBL] [Abstract][Full Text] [Related]
15. Decreased expression of long non-coding RNA NBAT-1 is associated with poor prognosis in patients with clear cell renal cell carcinoma.
Xue S; Li QW; Che JP; Guo Y; Yang FQ; Zheng JH
Int J Clin Exp Pathol; 2015; 8(4):3765-74. PubMed ID: 26097558
[TBL] [Abstract][Full Text] [Related]
16. LZTS2: A novel and independent prognostic biomarker for clear cell renal cell carcinoma.
Peng Y; Greenland NY; Lang UE; Stohr BA
Pathol Res Pract; 2022 Apr; 232():153831. PubMed ID: 35287088
[TBL] [Abstract][Full Text] [Related]
17. Integrated multi-omics characterization reveals a distinctive metabolic signature and the role of NDUFA4L2 in promoting angiogenesis, chemoresistance, and mitochondrial dysfunction in clear cell renal cell carcinoma.
Lucarelli G; Rutigliano M; Sallustio F; Ribatti D; Giglio A; Lepore Signorile M; Grossi V; Sanese P; Napoli A; Maiorano E; Bianchi C; Perego RA; Ferro M; Ranieri E; Serino G; Bell LN; Ditonno P; Simone C; Battaglia M
Aging (Albany NY); 2018 Dec; 10(12):3957-3985. PubMed ID: 30538212
[TBL] [Abstract][Full Text] [Related]
18. Plasma Mucin-1 (CA15-3) Levels in Autosomal Dominant Tubulointerstitial Kidney Disease due to MUC1 Mutations.
Vylet'al P; Kidd K; Ainsworth HC; Springer D; Vrbacká A; Přistoupilová A; Hughey RP; Alper SL; Lennon N; Harrison S; Harden M; Robins V; Taylor A; Martin L; Howard K; Bitar I; Langefeld CD; Barešová V; Hartmannová H; Hodaňová K; Zima T; Živná M; Kmoch S; Bleyer AJ
Am J Nephrol; 2021; 52(5):378-387. PubMed ID: 34098564
[TBL] [Abstract][Full Text] [Related]
19. A MUCINs expression signature impacts overall survival in patients with clear cell renal cell carcinoma.
Meng H; Jiang X; Huang H; Shen N; Guo C; Yu C; Yin G; Wang Y
Cancer Med; 2021 Sep; 10(17):5823-5838. PubMed ID: 34327857
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-194 is a Marker for Good Prognosis in Clear Cell Renal Cell Carcinoma.
Nofech-Mozes R; Khella HW; Scorilas A; Youssef L; Krylov SN; Lianidou E; Sidiropoulos KG; Gabril M; Evans A; Yousef GM
Cancer Med; 2016 Apr; 5(4):656-64. PubMed ID: 26860079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
